David Chan

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

Genotyping Informatics and Quality Control for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort

Mark Kvale, Stephanie Hesselson, Thomas J. Hoffmann et al. · Genetics · 2015 · 228 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Sara A. Hurvitz, Miguel Martín, Michael F. Press et al. · Clinical Cancer Research · 2019 · 220 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Justin Jee, Emily S. Lebow, Randy Yeh et al. · Nature Medicine · 2022 · 185 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score

David Chan, Aimee R. Hayes, Ioannis Karfis et al. · British Journal of Cancer · 2022 · 88 citations · Full text

Medicine, Nuclear Medicine, Radiology +17